Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953093 · ClinicalTrials.gov registry record · Phase 2
Study of Acarbose in Longevity
A Phase 2 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02953093: Clinical Trial Phase 2 study, sponsored by Montefiore Medical Center.
NCT02953093 is a Phase 2 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02953093, a Phase 2 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.
Primary Outcome
Difference in gene expression in muscle and abdominal adipose tissue using RNA-Seq were to have been evaluated to assess the effects of absorbed metabolites on tissues. Muscle and adipose are key metabolic tissues that undergo significant age-related changes and play an active role in the pathogenesis of aging. Muscle and abdominal adipose tissue samples were obtained and homogenized with tissue homogenizer. Subsequent mRNA extraction and analysis of gene expression (RNA seq) was conducted using
Interventions
- OTHER Placebo
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2019-12-26 |
| Phase | Phase 2 |
Why NCT02953093 stopped before completion
NCT02953093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02953093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02953093 about?
NCT02953093 is a clinical study titled "Study of Acarbose in Longevity". The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.
What is the current status of trial NCT02953093?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-08-30. Estimated completion is 2019-12-26.
What interventions are being tested in trial NCT02953093?
The interventions under investigation include: Placebo (OTHER), Acarbose (DRUG).
Who is sponsoring clinical trial NCT02953093?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02953093's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI